Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.
2.

A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.

Yamazaki K, Hironaka S, Boku N, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Hasuike N, Inui T, Yamaguchi Y, Ono H.

Int J Clin Oncol. 2008 Apr;13(2):150-5. doi: 10.1007/s10147-007-0738-y. Epub 2008 May 8.

PMID:
18463960
3.

Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.

Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, Li X, Tucker SJ, Zhong B, Cao Z, Wang D.

J Thorac Oncol. 2009 Aug;4(8):1017-21. doi: 10.1097/JTO.0b013e3181add9c7.

4.

Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.

Kajiura S, Hosokawa A, Yoshita H, Ueda Y, Ueda A, Mihara H, Ando T, Fujinami H, Nishikawa J, Ogawa K, Minemura M, Sugiyama T.

Am J Clin Oncol. 2016 Feb;39(1):13-7. doi: 10.1097/COC.0000000000000018.

PMID:
24322336
5.

A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.

Nakajima Y, Suzuki T, Haruki S, Ogiya K, Kawada K, Nishikage T, Nagai K, Kawano T.

Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1631-5.

PMID:
19102357
6.

Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.

Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y, Sakata Y, Ishioka C.

Int J Clin Oncol. 2006 Dec;11(6):454-60. Epub 2006 Dec 25.

PMID:
17180514
8.

Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.

Fujita Y, Hiramatsu M, Kawai M, Sumiyoshi K, Nishimura H, Tanigawa N.

Dis Esophagus. 2008;21(6):496-501. doi: 10.1111/j.1442-2050.2007.00806.x.

PMID:
18840134
9.

Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.

Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP.

J Clin Oncol. 1998 May;16(5):1826-34.

PMID:
9586897
10.

A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.

Akutsu Y, Shuto K, Kono T, Uesato M, Hoshino I, Shiratori T, Miyazawa Y, Isozaki Y, Akanuma N, Matsubara H.

Hepatogastroenterology. 2012 Oct;59(119):2095-8.

PMID:
22328303
11.

Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.

Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, Borsellino N, Pandolfo G, Durini E, Rinaldi M, Loizzi M, Gebbia N, Valenza R, Tirrito ML, Varvara F, Colucci G; Gruppo Ocologico Italia Meridionale.

Lung Cancer. 2003 Feb;39(2):179-89.

PMID:
12581571
12.

Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.

Zhang F, Wang Y, Wang ZQ, Sun P, Wang DS, Jiang YX, Zhang DS, Wang FH, Xu RH, Li YH.

Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12490. Review.

PMID:
27868295
13.

[Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].

Zhang L, Zhang Y, Li N, Xu F, Pan ZK, Guan ZZ.

Ai Zheng. 2004 Nov;23(11 Suppl):1455-8. Chinese.

PMID:
15566656
14.

Gemcitabine plus nedaplatin as salvage therapy is a favorable option for patients with progressive metastatic urothelial carcinoma after two lines of chemotherapy.

Matsumoto K, Mochizuki K, Hirayama T, Ikeda M, Nishi M, Tabata K, Okazaki M, Fujita T, Taoka Y, Iwamura M.

Asian Pac J Cancer Prev. 2015;16(6):2483-7.

15.

Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.

Paramanathan A, Solomon B, Collins M, Franco M, Kofoed S, Francis H, Ball D, Mileshkin L.

Clin Lung Cancer. 2013 Sep;14(5):508-12. doi: 10.1016/j.cllc.2013.03.007. Epub 2013 Jun 20.

PMID:
23792009
16.

Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.

Urba SG, Chansky K, VanVeldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, Abbruzzese JL; Southwest Oncology Group Study.

Invest New Drugs. 2004 Jan;22(1):91-7.

17.

Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors.

Shiraishi T, Nakamura T, Mikami K, Takaha N, Kawauchi A, Miki T.

Int J Clin Oncol. 2009 Oct;14(5):436-41. doi: 10.1007/s10147-009-0899-y. Epub 2009 Oct 25.

PMID:
19856053
18.

A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.

Lee DH, Kim HT, Han JY, Lee SY, Yoon SJ, Kim HY, Lee JS.

Cancer Chemother Pharmacol. 2008 Jan;61(1):83-8. Epub 2007 Apr 28.

PMID:
17468871
19.

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.

Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group.

Lancet Oncol. 2015 Dec;16(16):1630-8. doi: 10.1016/S1470-2045(15)00305-8. Epub 2015 Oct 28.

PMID:
26522337
20.

Long-term outcomes of gemcitabine and cisplatin in patients with recurrent or metastatic esophageal squamous cell carcinoma: a phase II trial.

Huang J, Fan QX, Chen L, Liu AN, Cai RG, Hao XZ, Wang JW, Sun Y.

Chin Med J (Engl). 2011 Dec;124(23):4012-7.

PMID:
22340334

Supplemental Content

Support Center